|会社名||Correvio Pharma Corp （カルディオ―ム・ファ―マ）|
|分野（sector）||Health Care ヘルスケア|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops acquires and commercializes brands for the in-hospital acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome as well as Esmocard and Esmocard Lyo a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent a drug device combination that is designed to deliver treprostinil. カルディオ―ム・ファ―マは、カナダのバイオ医薬品会社。心臓病患者の健康状態を改善する心血管治療法の開発と実用化に注力する。欧州連合（EU）と約50カ国で承認されている同社の製品「BRINAVESS」は、心房細動の心臓手術後3日以内の患者へ使用される。他にも、細胞タンパク質を調整する様々な心臓疾患治療のために、臨床前プロジェクトをもつ。 Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.|
|本社所在地||1441 Creekside Drive Vancouver British Columbia V4S 4J7 CAN|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Correvio Pharma Corp revenues increased 16% to $12.7M. Net loss decreased 80% to $3M. Revenues reflect Europe segment increase of 61% to $8M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.46 to -$0.09.|
Correvio Pharma (CORV) Reports Q4 Loss, Misses Revenue Estimates 2020/03/30 18:25:02 Zacks Investment Research
Correvio (CORV) delivered earnings and revenue surprises of 23.08% and -1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Correvio Pharma (CORV) Report Negative Q4 Earnings? What You Should Know 2020/03/04 17:30:29 Zacks Investment Research
Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORREVIO INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Correvio Pharma Corp. To Contact The Firm 2020/01/31 19:50:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Correvio Pharma Corp. (“Correvio” or the “Company”) (NASDAQ:CORV) of the February 10, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Correvio stock or options between October 23, 2018 and December 5, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/CORV.
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Correvio Pharma Corporation 2020/01/02 17:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CORV--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Correvio Pharma Corporation
TOP RANKED ROSEN LAW FIRM Reminds Correvio Pharma Corp. Investors of Important Deadline in Securities Action– CORV 2019/12/24 16:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Correvio Pharma Corp. (NASDAQ: CORV) between October 23, 2018 and December 5, 2019, inclusive (the “Class Period”) of the important February 10, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Correvio investors under the federal securities laws. To join the Correvio class action, go to http://www.rosenlegal.com/cases-register-17
関連キーワード （医薬品 米国株 カルディオ―ム・ファ―マ CORV Correvio Pharma Corp.）